JP2014518276A5 - - Google Patents

Download PDF

Info

Publication number
JP2014518276A5
JP2014518276A5 JP2014519158A JP2014519158A JP2014518276A5 JP 2014518276 A5 JP2014518276 A5 JP 2014518276A5 JP 2014519158 A JP2014519158 A JP 2014519158A JP 2014519158 A JP2014519158 A JP 2014519158A JP 2014518276 A5 JP2014518276 A5 JP 2014518276A5
Authority
JP
Japan
Prior art keywords
composition
concentration
isolated polypeptide
arginine
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014519158A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518276A (ja
JP6463968B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/044988 external-priority patent/WO2013006454A1/en
Publication of JP2014518276A publication Critical patent/JP2014518276A/ja
Publication of JP2014518276A5 publication Critical patent/JP2014518276A5/ja
Application granted granted Critical
Publication of JP6463968B2 publication Critical patent/JP6463968B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014519158A 2011-07-01 2012-06-29 アルギニンを含まない腫瘍壊死因子受容体:fc融合ポリペプチド組成物およびその使用方法 Active JP6463968B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161504110P 2011-07-01 2011-07-01
US61/504,110 2011-07-01
PCT/US2012/044988 WO2013006454A1 (en) 2011-07-01 2012-06-29 Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017098806A Division JP2017186349A (ja) 2011-07-01 2017-05-18 アルギニンを含まない腫瘍壊死因子受容体:fc融合ポリペプチド組成物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2014518276A JP2014518276A (ja) 2014-07-28
JP2014518276A5 true JP2014518276A5 (enExample) 2015-08-13
JP6463968B2 JP6463968B2 (ja) 2019-02-06

Family

ID=46579322

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014519158A Active JP6463968B2 (ja) 2011-07-01 2012-06-29 アルギニンを含まない腫瘍壊死因子受容体:fc融合ポリペプチド組成物およびその使用方法
JP2017098806A Pending JP2017186349A (ja) 2011-07-01 2017-05-18 アルギニンを含まない腫瘍壊死因子受容体:fc融合ポリペプチド組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017098806A Pending JP2017186349A (ja) 2011-07-01 2017-05-18 アルギニンを含まない腫瘍壊死因子受容体:fc融合ポリペプチド組成物およびその使用方法

Country Status (13)

Country Link
US (2) US10995130B2 (enExample)
EP (1) EP2726090B1 (enExample)
JP (2) JP6463968B2 (enExample)
KR (1) KR102061355B1 (enExample)
CN (2) CN103930124B (enExample)
AU (2) AU2012279205B2 (enExample)
BR (1) BR112013033671B1 (enExample)
CA (1) CA2840711C (enExample)
DK (1) DK2726090T3 (enExample)
EA (1) EA026226B1 (enExample)
MX (2) MX421100B (enExample)
WO (1) WO2013006454A1 (enExample)
ZA (1) ZA201400490B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
SG10201601621PA (en) 2011-06-28 2016-04-28 Inhibrx Llc Serpin fusion polypeptides and methods of use thereof
CA2840711C (en) 2011-07-01 2023-10-17 Biogen Idec Ma Inc. Arginine-free tnfr:fc-fusion polypeptide compositions and methods of use
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
IN2014CN02527A (enExample) * 2011-10-18 2015-06-26 Coherus Biosciences Inc
HK1209343A1 (en) * 2012-07-09 2016-04-01 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
LT2892550T (lt) 2012-09-07 2020-04-10 Coherus Biosciences, Inc. Stabilios adalimumabo vandeninės kompozicijos
CA2882551A1 (en) 2012-09-11 2014-03-20 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
JP6026002B2 (ja) * 2012-11-27 2016-11-16 アルテオジェン インコーポレイテッド タンパク質とFcドメインを融合した融合タンパク質の安定化用組成物
MX2015015051A (es) * 2013-05-02 2016-06-10 Mabxience S A Formulaciones alternativas para polipeptidos de fusion tnfr:fc.
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Meiji Seikaファルマ株式会社 安定化されたポリペプチド水性製剤
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
LT2946765T (lt) 2014-05-23 2016-11-25 Ares Trading S.A. Skysta farmacinė kompozicija
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
BR112017013269A2 (pt) 2014-12-22 2018-02-27 Ares Trading S.A. ?composição farmacêutica líquida?
KR20240132521A (ko) * 2015-03-13 2024-09-03 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
KR20180046888A (ko) * 2016-10-28 2018-05-09 (주)셀트리온 안정한 약제학적 제제
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201901547D0 (en) * 2019-02-05 2019-03-27 Arecor Ltd Stabilized Fc Fusion protein solutions
CN118510549A (zh) * 2021-09-22 2024-08-16 圣诺制药公司 具有减小的纳米颗粒尺寸和改善的多分散性指数的纳米颗粒药物组合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EP1171148A2 (en) 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
MXPA04007924A (es) * 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
WO2003072060A2 (en) 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
EP1946776B1 (en) * 2002-02-27 2017-01-18 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
KR100471843B1 (ko) 2002-06-11 2005-03-08 현대자동차주식회사 자동차의 아웃사이드 웨더스트립 장착구조
SI3417875T1 (sl) 2003-02-10 2021-01-29 Biogen Ma Inc. Formulacija imunoglobulina in metode za njegovo pripravo
EP1603596B1 (en) * 2003-02-28 2008-05-07 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding protein tbp-1
EP1654281A1 (en) * 2003-08-01 2006-05-10 Amgen, Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
EP3673919A1 (en) * 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
US20110046059A1 (en) * 2005-09-06 2011-02-24 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
AU2007240732B2 (en) * 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
ES2925992T3 (es) 2006-10-20 2022-10-20 Amgen Inc Formulaciones estables de polipéptidos
WO2008127975A2 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
NZ585702A (en) * 2007-11-30 2013-08-30 Abbott Lab Protein formulations and methods of making same
US20130209465A1 (en) * 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
CA2840711C (en) 2011-07-01 2023-10-17 Biogen Idec Ma Inc. Arginine-free tnfr:fc-fusion polypeptide compositions and methods of use

Similar Documents

Publication Publication Date Title
JP2014518276A5 (enExample)
RU2013151303A (ru) СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc
JP2020138981A5 (enExample)
EP2726090B1 (en) Arginine - free tnfr : fc- fusion polypeptide compositions
CN103998060B (zh) 使用糖与多元醇的结合物稳定的依那西普制剂
JP2013518055A5 (enExample)
JP6444310B2 (ja) モノクローナル抗体の安定化方法
BR112015010235B1 (pt) formulação líquida de um conjugado de derivado de oxintomodulina de longa duração e método para a preparação da mesma
RU2015151606A (ru) Альтернативные составы для химерных полипептидов tnfr:fc
JPWO2015190378A1 (ja) 安定なアダリムマブ水性製剤
EP2869816A1 (en) Etanercept formulations exhibiting marked reduction in sub-visible particles
JP2019536761A (ja) 液体医薬組成物
TWI728409B (zh) Hgf冷凍乾燥製劑
CN104936607A (zh) 稳定的TNFR:Fc融合蛋白药物组合物
JP2016502528A (ja) タンパク質とFcドメインを融合した融合タンパク質の安定化用組成物
WO2014178216A1 (ja) 水溶液製剤およびその製造方法
CN102441172B (zh) 高纯度凝血酶原复合物制品冷冻干燥稳定剂
JP2013510158A5 (enExample)
KR102692727B1 (ko) 수성 제제 및 주사기 내 수성 제제, 및 항체 단백질 탈응집제 및 항체 단백질 탈응집 방법
JP2021161101A (ja) 安定な抗ヒトpd−1抗体製剤
JP2016084329A (ja) 振とうストレス耐性を有するタンパク質の水性懸濁剤
TW201607564A (zh) 經安定化的多肽水性製劑
JPWO2023064886A5 (enExample)